Paper Details

  1. Home
  2. Paper Details

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).

Author: , AulitzkyW, BornhäuserM, EhningerG, FiedlerF, HerbstR, HänelA, HänelM, KroschinskyF, LangeT, MaschmeyerG, MorgnerA, NeugebauerS, NiederwieserD, PeterN, PönischW, ScheteligJ, SchulzeA, Schäfer-EckartK, ThielA, WilhelmM

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

There is no standard treatment for patients with acute myeloid leukemia (AML) that hasn't responded to initial treatment or has returned after treatment. Cytarabine (Ara-C) is a key drug for AML, but the best way to give it (dose and schedule) is unclear. This study aims to find out how the way Ara-C is given impacts patients with relapsed or refractory AML.
Paper Details　
Original Abstract of the Article :
For patients with primary refractory or relapsed acute myeloid leukemia (AML), no treatment of choice has until now been defined to date. Cytarabine (Ara-C) is a key drug in the treatment of AML patients, there is still uncertainly regarding its optimal dose and infusion schedule. The aim of this st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdv205

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Refractory AML: Mito-FLAG with Ara-C

Acute myeloid leukemia (AML), a type of blood cancer, can be a challenging condition to treat, particularly in cases of relapse or refractoriness. This study explores the effectiveness of a combination therapy involving Mito-FLAG, a chemotherapy regimen, and cytarabine (Ara-C), a commonly used anti-cancer drug, in patients with relapsed or refractory AML. The study aimed to determine the optimal infusion schedule for Ara-C in this setting, finding that the choice of infusion schedule can significantly impact treatment outcomes.

A More Personalized Approach to AML Treatment

This research underscores the importance of considering individualized treatment approaches for patients with relapsed or refractory AML. The study's findings highlight the significant impact of Ara-C infusion schedule on treatment outcomes. This information can help guide clinicians in tailoring treatment strategies to the specific needs of individual patients, potentially improving treatment effectiveness and prolonging survival.

The Shifting Sands of AML Treatment: A Call for Personalized Approaches

This study highlights the complexities of treating relapsed or refractory AML, a condition that often presents unique challenges. The findings emphasize the importance of considering individual patient factors when determining the best treatment approach. This research underscores the need for continued research and development of novel treatment strategies for AML, particularly in challenging cases.

Dr.Camel's Conclusion

This study emphasizes the need for a personalized approach to AML treatment, particularly in the challenging landscape of relapsed or refractory cases. The findings suggest that the optimal infusion schedule for Ara-C can significantly impact outcomes. This research underscores the importance of continuing to refine and personalize treatment strategies for AML, seeking new oases of knowledge in the vast desert of cancer research.

Date :
  1. Date Completed 2016-04-05
  2. Date Revised 2020-02-06
Further Info :

Pubmed ID

25922062

DOI: Digital Object Identifier

10.1093/annonc/mdv205

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.